Endovia Health Sciences, Inc.

EDVA

Last

$0.16

Day

-2.4%

—

52w

—

SPY YTD

+13.3%

XLV

+8.1%

Earnings

2026-11-1839d

EMA 21

—

EMA 50

—

EMA 200

—

20d high

—

5y high

—

5y range

—

Website · 1 employees · United States

Positions held

Your positions

EDVA isn't in your positions.

Add it to see shares, cost, and P&L here.

Score

—

Hold

—

Signal

—

Target

—

Stop

—

Stop distance

—

Target vs last

—

Fundamentals

Market cap	$1.77M	Enterprise value	$7.17M	Trailing P/E	—	Forward P/E	—
PEG	—	Price / book	-0.04	Beta	-1.15	Dividend yield	0.00%
Revenue growth	—	Earnings growth	—	Gross margin	0.0%	Operating margin	-451.6%
Profit margin	0.0%	ROE	—	ROA	-77.7%	Debt / equity	—
Current ratio	0.05	Free cash flow	$2.23M	Analyst recommendation	none	Mean target	—
52w high	$13.40	52w low	$0.15

Quarterly

	2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1
Revenue	$0.0M	$0.0M	-$0.4M	$0.0M	$0.0M	—
Op margin	—	-23176.4%	267.4%	—	—	—
Net income	-$2.1M	-$2.1M	-$3.2M	-$9.9M	-$8.5M	—
Gross margin	—	43.8%	-13.0%	—	—	—
Gross profit	$0.0M	$0.0M	$0.0M	$0.0M	$0.0M	—
Operating income	-$2.0M	-$1.0M	-$1.0M	-$9.5M	-$1.5M	—

Revenue -100% vs prior quarter ($0 vs $0.0M).
Gross margin 43.7% (was -13% prior quarter).
Operating margin compressed to -23176.4%.

Yearly (6y)

	2025	2024	2023	2022	2021
Revenue	$0.1M	$0.8M	$18.9M	$18.1M	—
Op margin	-19415.6%	-1235.6%	-81.1%	-118.3%	—
Net income	-$25.2M	-$23.8M	-$21.0M	-$21.7M	—
Gross margin	23.1%	-15.0%	29.5%	32.7%	—
Gross profit	$0.0M	-$0.1M	$5.6M	$5.9M	—
Operating income	-$14.2M	-$9.9M	-$15.3M	-$21.4M	—

Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-10-05 · Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

2026-09-22 · Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways

2026-08-31 · Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

2026-08-25 · Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program

2026-08-21 · Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Price (daily)

Full chart · RSI · MACD · patterns

No price history yet for EDVA.

Quarterly · revenue, net income, margins

Revenue Net income Gross margin Op margin